Showing 3281-3290 of 4063 results for "".
- Pixium Vision Complete Reverse Stock Splithttps://modernod.com/news/pixium-vision-complete-reverse-stock-split/2481842/Pixium Vision announced the completion of a reverse stock split, as decided by its Board of Directors on July 27, 2023, on the basis of 1 new share for 50 existing shares. Shareholders who could not hold a multiple of 50 existing shares will be automatically compensated of their fractio
- Bausch + Lomb’s ONE by ONE and Biotrue Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winnerhttps://modernod.com/news/bausch-lombs-one-by-one-and-biotrue-eye-care-recycling-programs-recognized-as-sustainability-service-of-the-year-award-winner/2481839/Bausch + Lomb announced that its ONE by ONE and Biotrue Eye Care Recycling programs have been recognized as 2023 Sustainability Award winners by Business Intelligence Group in the “Sustainability Service of the Year” category. “Millions of people wear co
- Sight Sciences Appoints Matt Link as Chief Commercial Officerhttps://modernod.com/news/sight-sciences-appoints-matt-link-as-chief-commercial-officer/2481835/Sight Sciences announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. Mr. Link has more than 20 years of experience building teams and leading innovation in the health care and medical technology industries, most recently serving as Mana
- DigitalOptometrics to Demonstrate Its Remote Comprehensive Exam Services With Instant Language Translation Capabilities at Vision Expo Westhttps://modernod.com/news/digitaloptometrics-to-demonstrate-its-remote-comprehensive-exam-services-with-instant-language-translation-capabilities-at-vision-expo-west/2481811/DigitalOptometrics, a provider of remote comprehensive eye exam services, will demonstrate its technology at Vision Expo West, September 28-30. Attendees can interact with a remote optometrist in real-time and experience a patient-centric comprehensive eye exam conducted via high-definition
- CooperVision to Spotlight Myopia Control and Management Advocacy at ESCRShttps://modernod.com/news/coopervision-to-spotlight-myopia-control-and-management-advocacy-at-escrs/2481809/CooperVision will spotlight advancing myopia control and management as standard of care across all ocular health sectors at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference in Vienna. On September 7, a thought leadership panel will be held
- Amgen and Horizon Therapeutics Resolve FTC Lawsuit Clearing Path to Acquisitionhttps://modernod.com/news/amgen-and-horizon-therapeutics-resolve-ftc-lawsuitclearing-path-to-acquisition/2481806/Amgen and Horizon Therapeutics announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. The order clears a path forward to closing its planned $27.8-billion takeout 
- Johnson & Johnson Vision Announces Launch of Elita Platform to Correct Myopia with New SILK Procedurehttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-elita-platform-to-correct-myopia-with-new-silk-procedure/2481802/Johnson & Johnson Vision will launch the new Elita Platform at European Society of Cataract and Refractive Surgeons (ESCRS) Congress, September 8-12, 2023, in Vienna, Austria. The Elita Platform enables surgeons to perform refractive correction on patients w
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Apellis Announces Corporate Restructuring and Workforce Reductionhttps://modernod.com/news/apellis-announces-corporate-restructuring-and-workforce-reduction/2481797/Apellis Pharmaceuticals announced a corporate restructuring that it says will cut costs and position the company for long-term success. As part of the restructuring, Apellis said it is reducing headcount by approximately 225 employees, or about 25% of the current wo
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w